A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
April 14 (Reuters) – Nektar Therapeutics said on Thursday it had stopped all trials involving its key cancer drug following its failure in multiple studies, dragging the drug developer's shares down 23% in after-market trading.
The trials that Nektar stopped included those involving a combination of its drug bempegaldesleukin with Bristol Myers Squibb Co's (BMY.N) cancer drug Opdivo as well Merck & Co Inc's (MRK.N) cancer drug Keytruda. (https://bit.ly/3xy0moX)
Nektar and Bristol Myers were testing the combination therapy through an agreement signed in 2020, while the one with Keytruda involved a partnership entered with privately owned SFJ Pharmaceuticals last year. (https://bit.ly/3CGjdyK)
Nektar and Bristol Myers last month discontinued two late-stage studies testing their combination therapy in melanoma patients after one of the trials failed to meet its main goals. read more
On Thursday, Nektar and Bristol said the combination of drugs failed to meet goals in another late-stage study in patients with renal cell carcinoma, as well as in a study testing the therapy in urothelial carcinoma, a type of bladder cancer.
With Nektar now halting multiple trials of its key drug, the company said it expects to announce a new strategic plan to rein in spending to meet its cash runway goals.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved